Assessment of Changes in Body Composition After 3 Months of Dulaglutide Treatment

Overview

Journal Diabetes Metab Syndr Obes

Publisher Dove Medical Press

Specialty Endocrinology

Date 2024 Mar 20

PMID 38505539

Authors

Shuqin Chen

Xuepeng Wang

Yong Jin

Xueqin Chen

Qifa Song

Gang Wei

Li Li

Affiliations

Soon will be listed here.

Abstract

Background: Changes in body composition accompanied by glucagon-like peptide 1 receptor agonist (GLP-1RA) induced weight loss have drawn much attention. However, fewer studies have reported body composition changes in patients receiving dulaglutide therapy in Chinese population.

Methods: A total of 70 overweight/obese type 2 diabetes mellitus (T2DM) patients who received dulaglutide therapy were included. Clinical data were collected. Visceral fat area (VFA) and body composition were also measured. Changes in clinical indicators and body composition of patients before and after intervention were also analyzed. Correlation analysis and multiple linear regression model were used to evaluate the association between hemoglobin A1C (HbA1c) and body composition.

Results: The results showed that body weight (BW), VFA, body fat (BF), lean body mass (LBM), skeletal muscle mass (SMM) and water content were reduced after 3 months dulaglutide intervention. The lean body mass percentage (LBMP) and skeletal muscle mass percentage (SMMP) significantly increased. Moreover, there was no significant difference in bone mineral quality (BMQ) after the intervention. The multiple linear regression model revealed that the % change in BF was independently associated with % change in HbA1c (β = 0.449, t = 3.148, p=0.002).

Conclusion: These results indicate that dulaglutide intervention does not cause muscle and bone mass loss while inducing weight loss, and % change in BF was independently associated with improved glucose control during dulaglutide therapy. This study offers some positive results to support the clinical application of dulaglutide.

Citing Articles

Assessment of Changes in Body Composition After 3 Months of Dulaglutide Treatment [Response to Letter].

Chen S, Wang X, Jin Y, Chen X, Song Q, Wei G Diabetes Metab Syndr Obes. 2024; 17:1819-1820.

PMID: 38660463 PMC: 11042472. DOI: 10.2147/DMSO.S473832.

Assessment of Changes in Body Composition After 3 Months of Dulaglutide Treatment [Letter].

Panjaitan N, Handayani S, Lestari C Diabetes Metab Syndr Obes. 2024; 17:1725-1726.

PMID: 38645654 PMC: 11027923. DOI: 10.2147/DMSO.S471933.

References

Villareal D, Banks M, Siener C, Sinacore D, Klein S . Physical frailty and body composition in obese elderly men and women. Obes Res. 2004; 12(6):913-20. DOI: 10.1038/oby.2004.111. View

Ward L . Segmental bioelectrical impedance analysis: an update. Curr Opin Clin Nutr Metab Care. 2012; 15(5):424-9. DOI: 10.1097/MCO.0b013e328356b944. View

Gentilella R, Sesti G, Vazquez L, Sapin H, Reed V, Romera I . Dulaglutide is an effective treatment for lowering HbA1c in patients with type 2 diabetes regardless of body mass index. Diabetes Obes Metab. 2019; 21(12):2660-2666. DOI: 10.1111/dom.13853. View

Frias J, Bonora E, Nevarez Ruiz L, Li Y, Yu Z, Milicevic Z . Efficacy and Safety of Dulaglutide 3.0 mg and 4.5 mg Versus Dulaglutide 1.5 mg in Metformin-Treated Patients With Type 2 Diabetes in a Randomized Controlled Trial (AWARD-11). Diabetes Care. 2021; 44(3):765-773. PMC: 7896253. DOI: 10.2337/dc20-1473. View

Sun H, Saeedi P, Karuranga S, Pinkepank M, Ogurtsova K, Duncan B . IDF Diabetes Atlas: Global, regional and country-level diabetes prevalence estimates for 2021 and projections for 2045. Diabetes Res Clin Pract. 2021; 183:109119. PMC: 11057359. DOI: 10.1016/j.diabres.2021.109119. View

Enomoto M, Adachi H, Fukami A, Kumagai E, Nakamura S, Nohara Y . A Useful Tool As a Medical Checkup in a General Population-Bioelectrical Impedance Analysis. Front Cardiovasc Med. 2017; 4:3. PMC: 5288389. DOI: 10.3389/fcvm.2017.00003. View

Cheng L, Hu Y, Li Y, Cao X, Bai N, Lu T . Glucagon-like peptide-1 receptor agonists and risk of bone fracture in patients with type 2 diabetes: A meta-analysis of randomized controlled trials. Diabetes Metab Res Rev. 2019; 35(7):e3168. DOI: 10.1002/dmrr.3168. View

Li Y, Hansotia T, Yusta B, Ris F, Halban P, Drucker D . Glucagon-like peptide-1 receptor signaling modulates beta cell apoptosis. J Biol Chem. 2002; 278(1):471-8. DOI: 10.1074/jbc.M209423200. View

Shi L, Liu X, Shi Y, Li Q, Ma J, Li Y . Efficacy and safety of dulaglutide monotherapy compared with glimepiride in Chinese patients with type 2 diabetes: Post-hoc analyses of a randomized, double-blind, phase III study. J Diabetes Investig. 2019; 11(1):142-150. PMC: 6944837. DOI: 10.1111/jdi.13075. View

10.

Umek N, Horvat S, Cvetko E . Skeletal muscle and fiber type-specific intramyocellular lipid accumulation in obese mice. Bosn J Basic Med Sci. 2021; 21(6):730-738. PMC: 8554708. DOI: 10.17305/bjbms.2021.5876. View

11.

Lee L, Hsu P, Hsieh K, Chen Y, Chu L, Lu H . Standing 8-Electrode Bioelectrical Impedance Analysis as an Alternative Method to Estimate Visceral Fat Area and Body Fat Mass in Athletes. Int J Gen Med. 2021; 14:539-548. PMC: 7917329. DOI: 10.2147/IJGM.S281418. View

12.

Monami M, Dicembrini I, Nreu B, Andreozzi F, Sesti G, Mannucci E . Predictors of response to glucagon-like peptide-1 receptor agonists: a meta-analysis and systematic review of randomized controlled trials. Acta Diabetol. 2017; 54(12):1101-1114. DOI: 10.1007/s00592-017-1054-2. View

13.

Mesinovic J, Zengin A, de Courten B, Ebeling P, Scott D . Sarcopenia and type 2 diabetes mellitus: a bidirectional relationship. Diabetes Metab Syndr Obes. 2019; 12:1057-1072. PMC: 6630094. DOI: 10.2147/DMSO.S186600. View

14.

Zhang Y, Weng W, Xie B, Meng Y, Hao Y, Liang Y . Glucagon-like peptide-1 receptor agonists and fracture risk: a network meta-analysis of randomized clinical trials. Osteoporos Int. 2018; 29(12):2639-2644. DOI: 10.1007/s00198-018-4649-8. View

15.

De Marinis Y, Salehi A, Ward C, Zhang Q, Abdulkader F, Bengtsson M . GLP-1 inhibits and adrenaline stimulates glucagon release by differential modulation of N- and L-type Ca2+ channel-dependent exocytosis. Cell Metab. 2010; 11(6):543-553. PMC: 4310935. DOI: 10.1016/j.cmet.2010.04.007. View

16.

Wada S, Yasunaga Y, Oka K, Dan N, Tanaka E, Morita K . Submucosal fat accumulation in human colorectal tissue and its association with abdominal obesity and insulin resistance. United European Gastroenterol J. 2018; 6(7):1065-1073. PMC: 6137583. DOI: 10.1177/2050640618766926. View

17.

Pinar-Gutierrez A, Garcia-Fontana C, Garcia-Fontana B, Munoz-Torres M . Obesity and Bone Health: A Complex Relationship. Int J Mol Sci. 2022; 23(15). PMC: 9368241. DOI: 10.3390/ijms23158303. View

18.

Hu S, Wang S, Qi C, Gu S, Shi C, Mao L . Cost-Utility Analysis of Once-Weekly Semaglutide, Dulaglutide, and Exenatide for Type 2 Diabetes Patients Receiving Metformin-Based Background Therapy in China. Front Pharmacol. 2022; 13:831364. PMC: 8894868. DOI: 10.3389/fphar.2022.831364. View

19.

Yusta B, Baggio L, Estall J, Koehler J, Holland D, Li H . GLP-1 receptor activation improves beta cell function and survival following induction of endoplasmic reticulum stress. Cell Metab. 2006; 4(5):391-406. DOI: 10.1016/j.cmet.2006.10.001. View

20.

Brunani A, Perna S, Soranna D, Rondanelli M, Zambon A, Bertoli S . Body composition assessment using bioelectrical impedance analysis (BIA) in a wide cohort of patients affected with mild to severe obesity. Clin Nutr. 2021; 40(6):3973-3981. DOI: 10.1016/j.clnu.2021.04.033. View